[Form 4] Cadrenal Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. (CVKD) director, CEO and chairman Quang Pham reported a planned sale of 500 shares of common stock executed on 10/02/2025 under a Rule 10b5-1 trading arrangement at prices ranging from $14.04 to $14.27, with a weighted average price of $14.13. Following the transaction, Mr. Pham directly owns 202,133 shares and indirectly holds 200,000 shares through The PVBQ Living Trust, for which he is trustee and retains sole voting and dispositive power. The Form 4 was signed by an attorney-in-fact on 10/03/2025.

Positive

• Sale executed under a documented Rule 10b5-1 plan, indicating a pre‑arranged, compliant trading program
• Full disclosure of direct and indirect holdings: 202,133 direct shares and 200,000 indirect via The PVBQ Living Trust

Negative

• Disposition of 500 shares reduces direct holdings (though the change is small relative to total ownership)
• Form signed by attorney-in-fact rather than the reporting person (signature dated 10/03/2025)

Insights

Corporate Governance Expert

TL;DR: Sale executed under a Rule 10b5-1 plan; reporting shows ongoing disclosure compliance.

The filing states the 500-share sale was made pursuant to a documented 10b5-1 trading arrangement, which provides the reporting person an affirmative defense to insider trading claims when executed properly. The report discloses both direct and indirect holdings—202,133 direct and 200,000 indirect—clarifying control and beneficiary details for The PVBQ Living Trust.

This level of disclosure aligns with standard Section 16 reporting practices and aids transparency about insider ownership and intent.

Equity Analyst

TL;DR: The trade is small relative to holdings; no material change to ownership stakes is shown.

The reported disposition of 500 shares at a weighted average of $14.13 represents a de minimis reduction versus the disclosed combined beneficial ownership of 402,133 shares. The price range ($14.04–$14.27) is provided, but the filer notes that detailed per-price quantities are available upon request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pham Quang X

(Last) (First) (Middle)

C/O CADRENAL THERAPEUTICS, INC.,

822 A1A NORTH, SUITE 306

(Street)

PONTE VEDRA FL 32082

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/02/2025		S		500	D	$14.13(1)	202,133	D
Common Stock								200,000	I	The PVBQ Living Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $14.04 through $14.27, inclusive, having a weighted average price as shown in column 4 of $14.13. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and disposition power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

	/s/ Matthew K. Szot, Attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Cadrenal (CVKD) insider Quang Pham report on Form 4?

The filing reports a planned sale of 500 common shares on 10/02/2025 under a 10b5-1 arrangement at a weighted average price of $14.13.

How many CVKD shares does Quang Pham own after the transaction?

After the reported sale, Mr. Pham directly owns 202,133 shares and indirectly controls 200,000 shares through The PVBQ Living Trust.

Was the sale pre‑planned under a Rule 10b5-1 plan?

Yes. The Form 4 is checked to indicate the transaction was made pursuant to a Rule 10b5-1 trading arrangement.

What price range and weighted average are disclosed for the sale?

Shares were sold at prices ranging from $14.04 to $14.27, with a weighted average price of $14.13.

Who is the beneficiary of The PVBQ Living Trust?

The filing states Mr. Pham's child is the sole beneficiary of The PVBQ Living Trust, for which Mr. Pham is trustee with sole voting and dispositive power.